2022
OR13-2 Characterizing the Impact of Burosumab on Bone Health in Children with X-Linked Hypophosphatemia: Results from Year 1 of the Disease Monitoring Program
Carpenter T, Cassinelli H, Glorieux F, Hetzer J, Merritt J, Moreira C, Portale A, Ward L, Woo C, Imel E. OR13-2 Characterizing the Impact of Burosumab on Bone Health in Children with X-Linked Hypophosphatemia: Results from Year 1 of the Disease Monitoring Program. Journal Of The Endocrine Society 2022, 6: a191-a192. PMCID: PMC9624613, DOI: 10.1210/jendso/bvac150.395.Peer-Reviewed Original ResearchSerum alkaline phosphatase levelsNew safety concernsAlkaline phosphatase levelsLower limb deformitiesGroup 1Serum phosphorusGroup 2Group 3Burosumab therapyBone healthPhosphatase levelsHeight z-score changeLimb deformitiesHuman IgG1 monoclonal antibodyYear 1 visitRecombinant human IgG1 monoclonal antibodySerum phosphorus levelsZ-score changeYears of treatmentRadiographic Global ImpressionYear 1Safety concernsIgG1 monoclonal antibodyBone painDMP enrolment
2000
Phosphaturic Mesenchymal Tumor-Induced Rickets
Reyes-Múgica M, Arnsmeier S, Backeljauw P, Persing J, Ellis B, Carpenter T. Phosphaturic Mesenchymal Tumor-Induced Rickets. Pediatric And Developmental Pathology 2000, 3: 61-69. PMID: 10594133, DOI: 10.1007/s100249910008.Peer-Reviewed Original ResearchConceptsPhosphaturic mesenchymal tumorYears of ageMesenchymal tumorsComputerized tomographyMixed connective tissue variantConnective tissue variantLower extremity painPoor linear growthRight proximal tibiaSpindle cell neoplasmFibroma-like variantLeft mandibular ramusBone painOncogenic ricketsRachitic abnormalitiesLytic lesionsRadiographic evidenceSecond patientFirst patientMuscle weaknessOccult tumorsPatient 1Prominent vascularityChondroid materialFibroblast-like cells